

**BEST OF ELCC & ESMO BREAST 2024****12th June 2024****Time : 07:00 - 09:00 PM**

<b>Time</b>	<b>Topic</b>	<b>Speaker</b>
07:00 - 07:05 PM	<b>Setting a Context</b>	Dr. Aditya Sarin, Delhi
	Session 1: Lung Cancer	
07:05 - 07:20 PM	Guiding treatment decision choices: molecular pathology in EGFR-Mutant NSCLC	TBC
07:20 - 07:35 PM	Amivantamab plus chemotherapy vs chemotherapy in EGFR-mutany advanced NSCLC after progression on osimertinib: A post-Progression analysis of MARIPOSA-2	Dr. Jyoti Wadhwa
07:35 - 07:55 PM	<b>Industry Sponsored Session</b>	TBC
07:55 - 08:10 PM	Navigating the current treatment landscape for common EGFR-mutant NSCLC	Dr. Mukesh Bansal
08:10 - 08:35 PM	<b>Industry Sponsored Session</b>	TBC
08:35 - 08:50 PM	PACIFIC is the best approach for N2 disease	Dr. Deepak Singhla
08:50 - 09:05 PM	first line(11) osimertnib (osi) +_ platinum pemetrexed in egfr mutated(EGFRm) advanced NSCLC: FLAURA2 post-progression outcomes	Dr. Shyam Aggarwal
09:05 PM Onwards	Key Takeaways	Dr. Aditya Sarin, Delhi

**BEST OF ELCC & ESMO BREAST 2024****13th June 2024****Time : 07:00 - 09:20 PM**

<b>Time</b>	<b>Topic</b>	<b>Speaker</b>
07:00 - 07:05 PM	<b>Setting a Context</b>	Dr. Aditya Sarin, Delhi

	Session 2: Breast Cancer	
07:05 - 07:20 PM	Making personalized precision medicine a reality for breast cancer in 2024	Dr. Amit Verma
07:20 - 07:35 PM	HR-positive/HER2-negative: When to use CDK4/6 inhibitors, including gBRCA1/2mut patients?	Dr. Manish Singhal
07:35 - 07:55 PM	Exploring CDK4/6 inhibitor clinical data in HR+/HER2- early breast cancer	Dr Sameer Khatri
07:55 - 08:10 PM	Analyzing first-line CDK4/6 inhibitor clinical data in HR+/HER2- advanced breast cancer	TBC
08:10 - 08:30 PM	Optimizing HER2+ early breast cancer management: Where are we today?	Dr. Vineet Govinda Gupta
08:30 - 09:00 PM	<b>Industry Sponsored Session</b>	TBC
09:00 - 09:20 PM	Combination strategies: Focus on ADCs and IO-based strategies	Dr. Anbarasan Sekar
09:20 PM Onwards	Key Takeaways	Dr. Aditya Sarin, Delhi